

1 **A simple, sensitive and quantitative FACS-based test**
2 **for SARS-CoV-2 serology in humans and animals**

3
4 Agnès Maurel Ribes¹⁺, Pierre Bessière²⁺, Jean Charles Guéry³, Eloïse Joly
5 Featherstone⁴, Timothée Bruel⁵, Remy Robinot⁵, Olivier Schwartz⁵, Romain
6 Volmer², Florence Abravanel^{3,6}, Jacques Izopet^{3,6} and Etienne Joly^{7*}
7

8 1 : Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse,
9 31000, Toulouse, France

10 2 : Ecole nationale vétérinaire de Toulouse, Université de Toulouse, ENVT, INRAE,
11 IHAP, UMR 1225, Toulouse, France

12 3 : Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity),
13 Université de Toulouse, INSERM, CNRS, UPS, 31300 Toulouse, France

14 4 : York University Hospital, York YO31 8HE, UK

15 5: Institut Pasteur, Virus and Immunity Unit, CNRS-UMR3569, Paris, France

16 6: Université de Toulouse, INSERM, CNRS, UPS, 31300 Toulouse, France

17 7: Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse,
18 CNRS, Toulouse, 31000, France

19
20 +: AMR and PB made equivalent contributions to this work.

21 *: correspondence to EJ: atnjoly@mac.com
22

23 **Abstract**

24 Serological tests are important for understanding the physiopathology and following the
25 evolution of the Covid-19 pandemic. Assays based on flow cytometry (FACS) of tissue culture
26 cells expressing the spike (S) protein of SARS-CoV-2 have repeatedly proven to perform slightly
27 better than the plate-based assays ELISA and CLIA (chemiluminescent immuno-assay), and
28 markedly better than lateral flow immuno-assays (LFIA).
29 Here, we describe an optimized and very simple FACS assay based on staining a mix of two
30 Jurkat cell lines, expressing either high levels of the S protein (Jurkat-S) or a fluorescent protein
31 (Jurkat-R expressing m-Cherry, or Jurkat-G, expressing GFP, which serve as an internal negative
32 control). We show that the Jurkat-S&R-flow test has a much broader dynamic range than a
33 commercial ELISA test and performs at least as well in terms of sensitivity and specificity. Also, it
34 is more sensitive and quantitative than the hemagglutination-based test HAT, which we
35 described recently. The Jurkat-flow test requires only a few microliters of blood; thus, it can be
36 used to quantify various Ig isotypes in capillary blood collected from a finger prick. It can be
37 used also to evaluate serological responses in mice, hamsters, cats and dogs. FACS tests offer a
38 very attractive solution for laboratories with access to tissue culture and flow cytometry who
39 want to monitor serological responses in humans or in animals, and how these relate to
40 susceptibility to infection, or re-infection, by the virus, and to protection against Covid-19.

42 **Introduction**

43 Over the past year, our world has been thrown into disarray by a pandemic caused by a new
44 coronavirus, SARS-CoV-2. With a mortality rate around 1%, this new virus is not as pathogenic as
45 previous coronaviruses such as SARS-CoV (9.6%) and MERS (35%), but it transmits faster from
46 human-to-human (Fani et al. 2020), probably because of a large proportion (ca. 50%) of
47 asymptomatic carriers (Wu et al. 2021; Long et al. 2020). Consequently, in less than two years
48 since its discovery in Wuhan, China, SARS-CoV-2 has spread all over the world and caused more
49 than 200 millions confirmed cases and over 4 millions confirmed deaths (
50 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>).

51 Biotechnology has proven a great asset in combating the pandemic, with the rapid
52 development of diagnostic tests and, more recently, of vaccines. Diagnostic tests detect directly
53 either the viral nucleic acid or viral proteins in nasopharyngeal swabs. Serological tests, by
54 contrast, detect antibodies developed in response to infection by the virus or vaccination, or a
55 combination of the two. Since the presence of antibodies in serum usually correlates with
56 elimination of the virus and the patient's recovery, serological tests have not been very helpful
57 in the clinic. They have, however, proven an essential tool to follow the spread of the pandemic
58 by evaluating seroprevalence in populations, and they are now set to become essential to
59 evaluate the immunity of individuals as well as populations (Koopmans and Haagmans 2020).

60
61 Whilst several thousands of serological studies have been published by now, based on tests
62 performed in many millions of individuals, those myriad studies mostly document the
63 seroprevalence in certain populations at a given time (Chen et al. 2021), but information
64 regarding the actual protection afforded by immunity after infection by SARS-CoV-2, and how
65 this correlates with the presence of antibodies against the SARS-2 virus is only just starting to
66 come out (Lumley et al. 2021; Letizia et al. 2021; Abu-Raddad et al. 2021; Jeffery-Smith et al.
67 2021; R. A. Harvey et al. 2021; Garcia-Beltran et al. 2021).).

68 While these recent publications show that the presence of antibodies does correlate with
69 protection against the Covid-19 disease, and in particular against the more serious forms of the
70 disease, one of the more burning questions that remains to be answered is how long this
71 protection will last? Another crucial question concerns whether there will be differences in the
72 duration of this protection depending on which vaccine was used, and whether an individual
73 had been infected by the SARS-CoV-2 virus before, or after, being vaccinated.

74
75 Obtaining answers to this type of questions should be greatly facilitated by access to simple,
76 cheap and quantitative serological tests, which would work both in humans and in animal
77 models. To date, however, although a multitude of commercial serological tests have been
78 developed to detect the presence of antibodies in the serum of patients (Farnsworth and
79 Anderson 2020), those are mostly ill-suited for use in research laboratories, not only because of
80 their price, but also because they are not or only poorly quantitative.

81
82 The most commonly used methods for Covid-19 serodiagnostic are either ELISA (Enzyme-
83 Linked ImmunoSorbent Assays) or CLIA (ChemiLuminescent ImmunoAssays). Whilst those
84 methods show very good sensitivity and specificity, they also have several significant
85 drawbacks:

- 86 i) The commercial versions are based on using volumes of serum or plasma which exceed the
87 amounts which can be readily obtained by finger prick, and therefore require venipuncture,
88 and hence trained personnel to collect the samples, and elaborate logistics to handle those
89 samples.
90 ii) They are relatively expensive (ca. 500 € per plate of 90 tests for commercial ELISA or CLIA)
91 and not easily modular (i.e. a whole plate will often have to be used even if only a few tests
92 are to be performed). Whilst in-house ELISAs are a possible alternative, they are difficult to
93 standardize and require high amounts of recombinant antigen (Amanat et al. 2020).
94 iii) Whilst ELISA tests are quantitative, they tend to saturate rapidly, and thus show a relatively
95 limited dynamic range.
96 iv) Most commercial versions are designed to detect human antibodies, and thus cannot be
97 used to follow serological responses in animal models.

98
99 Early in the pandemic, because they could be used in a point of care setting on capillary
100 blood obtained by finger pricks, lateral-flow immune assays (LFIA) attracted considerable
101 attention as an alternative to the ELISA or CLIA plate-based methods. Dozens of versions were
102 developed by various commercial companies, and despite their relatively high price, such LFIAs
103 were used in scores of studies to evaluate the prevalence of sero-conversion in various
104 populations. Over time, however, the general performances of LFIAs have proven to be too low,
105 both for sensitivity and reliability, to be of real use in clinical settings, and even for
106 epidemiological studies (Adams et al. 2020; Mohit et al. 2021; Dortet et al. 2021; Moshe et al.
107 2021).

108
109 As an alternative to those various serological tests, we set out to develop a serological test
110 based on hemagglutination, with the aim of obtaining a method that would be both sensitive,
111 cheap, and could be used both in the laboratory, in field settings or as a point of care test,
112 without the requirement for any elaborate equipment. The HAT (HemAgglutination Test)
113 method is based on a single reagent, IH4-RBD, which binds to human red blood cells (RBC) via

114 the IH4 nanobody specific for human Glycophorin A and coats them with the RBD domain of the
115 SARS-CoV-2 virus (Townsend et al. 2021). HAT has a sensitivity of 90% and specificity of 99%,
116 and is now used by several laboratories worldwide for epidemiological and clinical studies
117 (Kamaladasa et al. 2021; Jayathilaka et al. 2021; Jeewandara et al. 2021; Ertesvåg et al. 2021).
118 To be able to perform HAT on whole blood with the sensitivity and simplicity which we set out
119 the reach, and to attempt to make it quantitative, various modifications and improvements had
120 to be tested, and in order to do this, we felt that we needed a simple quantitative test that
121 would allow us to evaluate the amount of antibodies present in the whole-blood samples we
122 were using more simply and cheaply than by using ELISA or CLIA.

123

124 In this regard, the S-flow test (Grzelak et al. 2020), which uses flow cytometry (FACS)
125 performed on human cells expressing the S protein, appeared as a very promising approach
126 since it is very simple to run and its performances compared favorably with three other
127 serological tests (two ELISA directed towards the S or N proteins, and a luciferase immuno-
128 precipitation system (LIPS) combining both N and S detection).

129 The S-flow method initially described used HEK cells (Grzelak et al. 2020), which are adherent
130 cells. We felt that it would be better to use cells growing in suspension, not only because it
131 makes it a lot easier to grow large numbers of cells, but also because those can be used directly,
132 without having to be detached from the plastic, which we feared could possibly alter the cells'
133 characteristics, and introduce a possible source of variability between assays.

134 In this regard, Horndler and colleagues have recently described an assay inspired by the S-
135 flow assay, but based on Jurkat cells expressing both the full-length native S-protein of SARS-
136 CoV-2 and a truncated form of the human EGFR protein, which is used as an internal control for
137 the expression level of the S protein (Horndler et al. 2021).

138 One of the caveats of using human cells to express the S protein, however, is that those cells
139 will also express other antigens, and MHC molecules in particular, which can be the targets of
140 allo-reactive antibodies present in certain individuals, and not others. The background level of
141 staining on Jurkat cells themselves will thus vary from sample to sample. To circumvent this
142 difficulty, Pinero et al. have used the Jurkat-S+EGFR cells mixed with untransfected Jurkat cells
143 as negative controls (Piñero et al. 2021).

144 Having followed the same reasoning as Horndler *et al.*, we had chosen to make use of Jurkat
145 cells expressing the native form of the spike protein of the SARS-CoV-2 virus, but we elected to
146 use Jurkat cells expressing the mCherry red fluorescent protein as negative controls. This is not
147 only cheaper because it does not require labelling the cells with an additional commercial
148 antibody, but also has the advantage of using two cell lines that are maintained in the same
149 selective tissue culture medium.

150 In all three papers (Horndler et al. 2021; Piñero et al. 2021; Grzelak et al. 2020), and several
151 others (Egia-Mendikute et al. 2021; Hambach et al. 2021; Lapuente et al. 2021; Goh et al. 2021),
152 the sensitivity of approaches based on flow cytometry was reported to be superior to those of
153 ELISA or CLIA, probably because such tests are based on detecting the spike protein expressed
154 in its native conformation.

155 Since the Jurkat-flow test calls for the use of both a flow cytometer and cells obtained by
156 tissue culture, it is clearly not destined to be used broadly in a diagnostic context, but its
157 simplicity, modularity, and performances both in terms of sensitivity and quantification
158 capacities should prove very useful for research labs working on characterizing antibody
159 responses directed against SARS-2, both in humans and animal models.

160 **Results and Discussion**

161

162 ***Jurkat-S&R-flow: basic principles***

163

164 Jurkat cells expressing high levels of the SARS-CoV-2 spike protein, which we subsequently
165 refer to as Jurkat-S, or J-S, were obtained by means of transduction with a lentiviral vector,
166 followed by three rounds of cell sorting. A second population of Jurkat cells, in which all cells
167 express the mCherry fluorescent protein, and which we subsequently refer to as Jurkat-R, or J-R,
168 was also obtained by lentiviral transduction (see M&M: Materials and Methods section).

169


170 For the Jurkat-S&R-flow test, we simply prepare a mix of equivalent numbers of the two cells
171 lines, J-S and J-R, and use either sera or plasma at a final dilution of 1/100 to label $2 \cdot 10^5$ cells of
172 this mix (see M&M for details). After this primary step of labelling, the cells are washed before
173 being incubated with a fluorescent secondary antibody, and a final wash is performed before
174 analysis by flow cytometry.

175

176 The advantage of using such an approach is that it guarantees that the test cells (Jurkat-S)
177 and the control cells (Jurkat-R) are labelled in exactly the same conditions. Comparing the levels
178 of staining between test and control cells can then be carried out without any risk of a
179 difference between the two being due to a difference in the course of the labelling procedure
180 (e.g. certain samples receiving less of the primary or secondary antibodies). Accessorily, another
181 significant advantage of such an approach is that it reduces the number of FACS samples to be
182 processed by a factor of two.

183

184 The mCherry signal allows simple separation by gating during analysis of the control cells
185 from the test cells (Figure 1). In samples labelled just with the secondary antibody (neg. cont.)
186 or with pre-pandemic plasma which does not contain antibodies against the spike protein (neg
187 plasma), similar green signals are found on J-S et J-R populations. When there are antibodies
188 against the spike protein present in the plasma or serum used to label the cells, this will result in
189 a marked difference in the green signals detected on the J-S cells compared to the J-R cells. The
190 difference in the fluorescence intensity between the two populations will provide a quantitative
191 evaluation of the amounts of antibodies in the serum or plasma used to label the cells (first
192 column). The numbers shown in red correspond to the relative specific staining (RSS = signal J-S
193 – signal J-R / signal neg. cont.).



194
195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

Figure 1: Basic principle and examples of the Jurkat-S&R-flow test

A 50/50 mix of Jurkat cells expressing either the S protein of the SARS-CoV-2 virus or the mCherry protein is first incubated with a 1/100 dilution of the plasma or serum sample to be tested, followed by incubation with a green fluorescent secondary antibody. The cells are then analyzed by flow cytometry.

The panels on the first line show the gating strategy, using as an example the sample of a negative control, stained only with an anti-human pan specific secondary antibody conjugated to alexa-488 : Live cells are first selected on a combination of two gates drawn on three parameters: size (FSC), granularity (SSC), and far red fluorescence (FL4) to eliminate the dead cells labelled by the Topro3 live stain. Jurkat-S are then distinguished from Jurkat-R cells using the red fluorescence of the latter, by means of a gate drawn on a FL1/FL3 dotplot. The gates had to be drawn that way to accommodate the fact that, for the brightest cells, the green fluorescent signal of alexa-488 can ‘bleed’ into the FL3 channel, and the Cellquest software does not allow for FL3/FL1 compensation. A histogram overlay is then drawn with the cells falling in each of these two gates (red: Jurkat-R, green: Jurkat-S). The numbers in the upper right corners of those histograms correspond to the GMFIs of the two histograms.

The red numbers shown to the left of the plots correspond to the relative specific staining (RSS; i.e. the difference of signal between J-S and J-R divided by the GMFI of the negative control, i.e. 2.00)

The first column shows examples of staining with 4 different plasmas which were either negative, or weakly, positively and strongly reactive with the spike protein.

The second column shows an example of the Jurkat-S&R-flow test capacity to perform a rough evaluation of the relative proportion of the various Ig isotypes in a sample, in this case the 20/130 reference serum obtained from the NIBSC.

The third column presents examples of some of the rare samples which showed various levels of allo-reactivity against the Jurkat cells themselves. Although the sample on the third line had an RSS of 30 (thus well above the threshold of 20 set for positivity), this sample was probably negative since it showed no reactivity in the other two serological tests. The sample on the fourth line shows that some sera can be both allo-reactive against the Jurkat cells, and strongly reactive against the spike protein.

223 If isotype-specific secondary reagents are used, an evaluation of the respective amounts of
224 various classes of antibodies can also be obtained (second column). It should, however, be
225 noted that, because different secondary reagents do not necessarily recognize the various Ig
226 isoforms with the same efficiency, this provides only a very rough analysis of the relative
227 amounts of Ig-G, -A and -M. Within a set of samples, however, this can provide very simple
228 means to compare samples with one another (Table S1).

229
230 As alluded to in the introduction, one of the possible caveats of using a human cell line to
231 express the S protein is that some blood samples will contain allo-reactive antibodies directed
232 against that cell line, possibly as a consequence of a pregnancy, or past history of receiving a
233 blood transfusion or organ transplant (Hickey et al. 2016; Karahan et al. 2020). The third column
234 of Figure 1 shows examples of such samples containing marked levels of alloreactive antibodies,
235 i.e. samples for which the J-R cells show significant levels of staining compared to the same cells
236 labelled with just the secondary antibody. Based on our results collected on more than 350
237 clinical samples, we evaluate that ca. 30 % of samples will contain allo-reactive Abs that will
238 result in levels of staining of Jurkat cells that are more than five-fold that of the signal obtained
239 for the negative control (and 3-6 % more than ten-fold). Of note, we did not notice an increased
240 frequency of allo-reactivity in samples from women compared to men, which suggests that allo-
241 reactivity after pregnancy is not a major cause in the origin of those allo-reactions.

242
243 A difficult question with all serological tests is that of where to set the threshold beyond
244 which the specific signals detected can confidently be considered as positive, which will be
245 directly linked to the balance between sensitivity and specificity of the assay. Based on the
246 analyses of various cohorts of positive and negative samples (some of which will be presented
247 further down in this manuscript), for the Jurkat-S&R-flow, we have settled for a threshold of RSS
248 =20, i.e. twenty-fold the value of the negative control stained just with secondary-antibodies.
249 The reason for using the geometric mean of fluorescence intensity (GMFI) of the negative
250 control as an internal reference is that, in flow cytometry, the numerical values of fluorescence
251 intensities will be totally dependent upon the cytometer settings, and the voltages applied to
252 the PMT in particular. But we find that this can be somewhat compensated by such an
253 approach. For example, in the conditions used in our experiments, the GMFI of the negative
254 control had a value of ca. 2 when analyzed on a FACScalibur flow cytometer. With a threshold
255 set at 20, samples were thus considered as positive if the difference in the GMFI of the J-S and J-
256 R populations was above 40 (numbers shown in red in Figure 1 are $J-S - J-R / 2$). When the very
257 same samples were analyzed on a Fortessa flow cytometer (Figure S1), the value of the GMFI for
258 the negative control was 24-fold higher, but the RSS values obtained closely resembled those
259 obtained with the same samples on the FACScalibur (red numbers in Figure S1 and Figure 1:
260 20/23; 366/378; 916/855; 490/508).

261
262 For the samples showing high levels of allo-reactive staining, however, it is worth underlining
263 that this threshold of 20 had to be considered with some caution. Indeed, in those allo-reactive
264 samples, such as the examples shown in the right column of Figure 1, we found that the
265 difference between the green signals recorded for the J-S and J-R populations can fluctuate
266 between experiments, presumably because those signals correspond to the recognition by allo-
267 reactive antibodies of cell surface markers that are not always expressed at the same levels in
268 all Jurkat cells. Such alloreactive signals can be higher in J-R for certain serum or plasma

269 samples, or in J-S for other samples (first vs second and third line), without, in this latter case,
270 necessarily corresponding to bona-fide reactivity against the spike protein of the SARS-CoV2
271 virus. The sample shown on the fourth line represents the most extreme case we have come
272 across, from a Covid-19 patient with extremely high allo-reactivity, coupled to bona fide
273 reactivity against the spike protein. All in all, it is simply worth underlining that, for the small
274 percentage of samples showing significant alloreactivity against Jurkat cells, and staining of
275 Jurkat-S slightly higher than that of Jurkat-R, their reactivity should be checked with a different
276 serological test before considering them as truly positive.

277
278 Inspection of the dot plot for this very alloreactive sample provides the explanation for the
279 slightly odd shapes of the FL1/FL3 gates we used to discriminate Jurkat-S from Jurkat-R cells.
280 This was necessary because, on the FACScalibur, the fluorescent signal of mCherry is best
281 captured by the FL3 channel, but the version of the Cellquest program used for acquisition on
282 this cytometer does not allow for FL3/FL1 compensation. Consequently, samples with extremely
283 high FL1 signals showed some 'bleeding' into the FL3 channel. We found that this could not be
284 satisfactorily treated by post-acquisition compensation with the Flowjo analysis software either,
285 and thus resorted to drawing such gates to separate J-S from J-R populations.

286
287 We had elected to use a green/red combination for test and control cells for two reasons: 1)
288 secondary antibodies labeled with green fluorescent dyes such as fluorescein or Alexa 488 are
289 the most commonly available, and also usually the cheapest. 2) All flow-cytometers, even the
290 most basic ones, are equipped with a 488 nm laser which allows to perform green/red analyses.
291 Another important consideration is that one of the goals of this study was to set up a test which
292 could be used by as many research teams as possible, including those based in institutes from
293 less affluent countries, which are less likely to have access to recent, state-of-the-art multi-laser
294 flow cytometers. As will be seen later, with secondary antibodies conjugated to Alexa-647 which
295 can be excited by the second 633 nm laser of the FACScalibur, it is possible to use Jurkat-GFP
296 cells as an alternative to J-R cells.

297
298 When the same samples as shown on Figure 1 were analyzed using a Fortessa flow
299 cytometer, the picture was quite different (Figure S1). This more recent flow cytometer is
300 endowed with several lasers, including a 561 nm Yellow-Green laser, which is much better
301 suited for the excitation of the mCherry fluorescent protein, thus yielding much higher signals
302 which, since they are acquired on a different laser line from the green signals, require absolutely
303 no compensation.

304
305 In many flow cytometry facilities, users are required to fix any samples that have been in
306 contact with materials of human origin. Whilst this was not the case for us, we still tried
307 analyzing the same samples after those were fixed with 1% formaldehyde and kept for 4 days at
308 4°C before re-analysis. As can be seen on the right part of Figure S1, formaldehyde-fixation
309 resulted in a 7-fold drop in the intensity of the mCherry signals, which made it impossible to
310 separate J-R from J-S populations on the FACScalibur (first line). On the other hand, analysis on
311 the Fortessa was still comfortably possible. Of note, whilst formaldehyde did not noticeably
312 alter the fluorescence signals of the alexa-488 dye, it did result in a twofold increase of the
313 green auto-fluorescence of the negative controls, hence resulting in a twofold reduction of the
314 RSS compared to those obtained on unfixed cells.

315 **Performance of the JurkatS&R-flow test on clinical samples**

316
317 Next, we compared the performance of the Jurkat-S&R-flow test with those of two other
318 serological tests: the Wantai commercial RBD ELISA test, and the hemagglutination-based test,
319 HAT (Townsend et al. 2021).


320
321 For this, we made use of two cohorts of clinical samples.

322 First, a preexisting cohort of 121 sera available in the virology laboratory of the Toulouse
323 hospital which had all previously been tested with the Wantai RBD ELISA test (Abravanel et al.
324 2020), comprising 40 negative serum samples collected before December 2020, and 81 sera
325 from PCR-positive subjects. For those samples, RBCs from O- donors were used to perform the
326 HAT tests (see M&M).

327 The second cohort consisted of 267 whole blood samples collected on EDTA, obtained from
328 the hematology department of the Toulouse hospital as left-over clinical material, for which we
329 have consequently very little clinical information. For those samples, the HAT test was
330 performed on whole blood, i.e. using the subjects' own RBCs for hemagglutination. The blood
331 samples were subsequently centrifugated, and the plasmas collected to perform the Jurkat-
332 S&R-flow and the RBD-ELISA tests.

333
334 The result of the analysis of these two cohorts with the three serological tests are presented
335 in Figure 2, with colors used to represent the HAT results.

336



337
338

339 **Figure 2: Comparison of the results of the 3 serological tests on two cohorts of clinical samples.**
340 Panel A: results obtained with a cohort of 121 serum samples (81 PCR pos, 40 neg) collected by the
341 virology department of the Purpan Hospital (Toulouse, France).
342 Panel B: results obtained with a cohort of 267 whole blood samples coming from the hematology
343 department of the Rangueil Hospital (Toulouse, France).
344 Each plot presents ELISA scores (Y axis) against the results of the Jurkat-S&R-flow tests, expressed as RSS.
345 For improved clarity, both axes are presented on log scales (for this, the negative RSS values of 4 samples
346 of the cohort on the right had to be manually converted to a value of 0.5).
347 Colors are used to represent the HAT results: red: positive, blue: negative, yellow: partially positive
348 hemagglutination, black: false positive, i.e. samples for which hemagglutination also occurred with the
349 IH4 nanobody not coupled to the RBD domain.

350 The results of the first cohort (Figure 2A) show a clear-cut dichotomy in the distribution of
351 the points, with two well separated clouds: one of blue points falling in the lower left quadrant,
352 and one of red points in the upper right one. In other words, for this cohort of sera collected
353 either from hospitalized Covid-19 patients or dating from before the pandemic for the negative
354 controls, the three tests are in almost perfect agreement for the discrimination between
355 positives and negatives, with just one yellow point in the lower right quadrant, i.e. positive for
356 the Jurkat-S&R-flow test, showing only partial hemagglutination, but the signal for the RBD-
357 ELISA test falling slightly below the threshold of 1 set by the manufacturer, suggesting that the
358 anti-viral serological response of this subject was probably focused on regions of the spike
359 protein outside of the RBD domain.

360
361 Of note, partial hemagglutination was also recorded for two other samples which were
362 negative for the two other tests. Those two samples were from a group of 38 patients
363 hospitalized for Covid-19, but for whom the blood had been collected less than 14 days after the
364 PCR diagnostic. This observation is in line with our previous observation that the HAT test may
365 be particularly performant for the detection of early serological responses, probably because of
366 a higher hemagglutinating capacity of IgMs (Townsend et al. 2021). Incidentally, in this same
367 group of 'early' PCR-positive Covid patients, there were also 4 other samples which were
368 negative for all three tests (see tables of data provided as supplementary material).

369
370 The results of the second cohort, which comprised a few Covid patients, but also a large
371 proportion of blood samples randomly picked among those from patients hospitalized for
372 conditions unrelated to Covid-19, yielded a much less clear picture than the first one. As can be
373 seen on Figure 2B, many of the dots for this cohort occupy a more intermediate position
374 between the two clouds of clearly positive and clearly negative samples. In the upper right
375 quadrant, one notices a relatively high proportion of blue and yellow spots, i.e. of HAT negative
376 or partial samples in the set which were positive with both the RBD-ELISA and Jurkat-S&R-flow
377 tests, albeit in the lower left part of the quadrant, i.e. rather weakly.

378
379 On the other hand, there are also a handful of samples in the lower left quadrant for which
380 partial or full hemagglutination was detected, which may correspond to early serological
381 responses. There are also a few blue dots in the upper left and lower right quadrant, thus
382 corresponding to samples being positive only either with the RBD ELISA or the Jurkat-S&R-flow
383 test. According to previous work, the sera which react weakly on the full length spike protein
384 expressed at the surface of Jurkat cells are most likely due to cross-reactivities with the S2
385 domain of other coronaviruses (Ng et al. 2020; Khan et al. 2020).

386
387 One additional conclusion that can be drawn from the comparison of the results of the RBD-
388 ELISA with those of the Jurkat-S&R-flow test is that, whilst the two methods show similar
389 sensitivities, the ELISA signals tend to saturate very rapidly, and are thus much less dynamic than
390 those obtained by flow cytometry.

391
392

393 ***Examples of possible uses of the Jurkat-flow test***

394
395 A further advantage of the Jurkat-S&R-flow test compared to the commercial RBD-ELISA we
396 used for this study is that it only requires 1 μ L of plasma or serum, compared to 100 μ L for the
397 ELISA, which makes it possible to perform on small volumes of capillary blood collected by finger
398 prick.

399
400 As a proof of concept that this was doable and useful, we used capillary blood which one of
401 the authors collected by pricking his finger at various intervals to document the time course of
402 his serological response after vaccination, and the results are shown in panel A of Figure 3. One
403 somewhat surprising finding was with the low levels of IgM recorded, which may in part be
404 explained by the fact that, as a rule, anti-IgM secondary antibodies tend not to work as well as
405 those against the other isotypes. One should note, however, that, with the same anti-IgM
406 secondary reagent, signals of the same order of magnitude were found for IgG and IgM with the
407 20/130 reference serum (Figure 1), as well as in several other samples (Table S1). The
408 observation that the signals obtained with an anti-IgG reagent are similar, and even often a bit
409 higher to those obtained with the pan-reactive anti-IgGAM is something which we tend to find
410 in most samples (Table S1), and which had already been underlined by Grzelak et al. in the
411 context of the S-flow test (Grzelak et al. 2020).

412
413 The capacity of the SARS-CoV-2 virus to infect primates, hamsters or ferrets has provided
414 very useful animal models to understand the physiopathology of Covid-19, whilst its capacity to
415 infect domestic pets such as cats and dogs does raise concerns about the transmissions of the
416 virus back to humans, as well as about the problem of animal reservoirs from which it will be
417 very difficult to eradicate the virus. Whilst scores of commercial and lab-made methods have
418 been described to follow human serological responses to the virus, there is a remarkable
419 paucity of tests available today applicable to animals. Since all it would take to adapt the Jurkat-
420 S&R-flow test to animals would be to use different species-specific secondary antibodies, we
421 explored whether this would work for mice, cats, dogs and hamsters.

422

Figure 3




Figure 3: Various examples of the possible uses of the Jurkat-flow test

Panel A: Monitoring serological responses in humans

The Jurkat-S&R-flow test was used to follow the serological response of an individual during the course of his vaccination (red arrows: first injection on day 0 and boost on day 27), with isotyping using specific secondary reagents performed as described in the M&M section. Y axis: Specific staining (GMFI J-S – GMFI J-R)

Panel B: The Jurkat-S&R-flow test can be used to follow Ig responses in mice.

Sera from three groups of mice having been immunized either once, twice or not by intra-peritoneal injection of inactivated SARS-CoV-2 virus were analyzed with the Jurkat-S&R-flow test, using an anti-mouse Ig secondary antibody. Y axis: GMFI on Jurkat-R (blue columns), on Jurkat-S (top of green columns), The specific signals correspond to the yellow or green portions (GMFI J-S – GMFI J-R).

Panel C: In cats and dogs, the results of the Jurkat-S&R-flow test correlate with those of seroneutralization titers.

Panels of sera from cats and dogs whose owners had recovered from symptomatic Covid-19 were used to perform both sero-neutralization assays and the Jurkat-S&R-flow test, using the corresponding secondary antibodies. Specific stain = GMFI J-S – GMFI J-R. *: the higher SN titers shown for the cat serum 66JQ was obtained on a different day from all the others.

Panel D: Monitoring of antiviral serological responses in Hamsters with the Jurkat-S&G-flow test

For this experiment, we used sera from 6 hamsters which had been experimentally infected with the UCN1 strain of SARS-CoV-2 15 days earlier, as well as 6 uninfected controls. Since we had an anti-hamster Ig secondary antibody conjugated to alexa 647, we used an S&G version of the test, with Jurkat cells expressing GFP as negative control, and propidium iodide to gate out dead cells (see M&M). As can be seen on the right side of the panel, in this configuration, no compensation was required, and separating the Jurkat-S test cells from the Jurkat-G control cells could be performed with simple square gates. And although the GFP signal was reduced after fixation of the cells in PFA for 24 hours analysis of cells was still possible with the FACScalibur, with almost no loss of the alexa 647 signal.

452 First, we used sera of mice which had been immunized once or twice with inactivated SARS-
453 CoV-2 virus injected intra-peritoneally. As can be seen on panel B of Figure 3, whilst the sera of
454 control mice did not react significantly with Jurkat cells, those of immunized mice showed
455 strong specific reactions against the spike protein, which were even higher in those having
456 received two injections. Of note, the reactions against the Jurkat-R cells also went up in
457 correlation with the injections, albeit to a much lesser degree than against the S protein. This is
458 presumably due to the fact that the preparations of inactivated virus used for the
459 immunizations probably contained some bovine proteins from the serum used in the tissue
460 culture medium that would have the capacity to bind to the surface of the Jurkat cells, such as,
461 for example, beta-2-microglobulin binding to MHC class I molecules. The Jurkat-S&R-flow
462 method therefore seems to work very satisfactorily in mice, and since it requires only a few μL
463 of blood, it is well suited to follow serological responses over time.

465 We then turned our attention to cats and dogs, which have both been shown to be
466 susceptible to infections by the SARS-CoV-2 virus (Sit et al. 2020; Drózdź et al. 2021; Bessièrè,
467 Fusade-Boyer, et al. 2021; Chen 2020), but for which one of the only reliable means to test for
468 the presence of a serological response is to perform sero-neutralization experiments, which are
469 both cumbersome and require access to BSL-3 facilities. For our exploratory experiments, we
470 simply used sets of sera collected from 11 cats and 11 dogs whose owners had had symptomatic
471 Covid-19 infections, and on those we performed both sero-neutralization experiments, and the
472 Jurkat-S&R-flow test, using the appropriate secondary antibodies. As can be seen on panel C of
473 Figure 3, we found a very good correlation between the levels of specific staining of Jurkat-S
474 cells and the neutralization titers of the same sera. Whilst those are very preliminary
475 observations which will need to be strengthened by many more samples, and in particular with
476 samples collected before the Covid-19 pandemic as negative controls, those results show that
477 the Jurkat-S&R-flow test can clearly be used to evaluate the levels of antibodies against the S
478 protein of the SARS-CoV-2 virus in cats and dogs.

480 Finally, we turned our attention to hamsters, which are susceptible to infection by SARS-CoV-
481 2, and have been a very useful animal model to study the physiopathology of the infection. For
482 this, we made use of a panel of sera from hamsters which had been used in a previous study
483 (Bessièrè, Wasniewski, et al. 2021). Because we had some anti-hamster Ig conjugated to the
484 Alexa -647 fluorochrome at our disposal, we took this opportunity to test the possibility of
485 adapting the Jurkat-S&R-flow test to a Jurkat-S&G-flow test, i.e. using Jurkat cells expressing
486 GFP rather than mCherry as the internal negative control. As can be seen on panel D of figure 3,
487 the sera from the hamsters that had been experimentally inoculated with the SARS-CoV-2 virus
488 two weeks earlier all harbored very high levels of antibodies against the virus, whilst no signal
489 was detected with the sera from control animals. Of note, with the S&G version of the test, i.e.
490 using GFP-expressing Jurkat cells as negative control and a secondary antibody conjugated to
491 alexa-647, since the two signals were collected on the separate green and red laser lines of the
492 FACScalibur, the situation was similar to when we analyzed the Jurkat-S&R-flow test on a
493 Fortessa flow cytometer: gating to separate the test from the control cells was achieved with
494 simple rectangular gates, and although fixation in PFA resulted in a twofold reduction of the GFP
495 fluorescent signal, and the auto-fluorescence of the Jurkat-S cells increased about threefold, the
496 efficient triggering of GFP by the 488 nm laser meant that the test and control populations could

497 still be separated and analyzed after fixation, albeit staining with propidium iodide could no
498 longer be used to gate out dead cells.

499

500 **Concluding remarks and perspectives**

501

502 Given its versatility, flexibility and affordability, we believe that the Jurkat-S&R-flow or
503 Jurkat-S&G-flow assays could prove useful for many research scientists wanting to measure
504 serological responses directed towards the spike protein of the SARS-CoV-2 virus, either in
505 humans, or in animals, but who would not have either the financial means to purchase
506 commercial plate-based assays such as ELISA or CLIA, or access to the sizeable amounts of
507 recombinant proteins required to set those up in-house. The Jurkat-flow tests could be
508 performed by any laboratory with access to tissue culture and to a flow cytometer, at a cost of
509 roughly 10 cents per sample (see M&M for calculation). It is thus much cheaper than
510 commercial ELISAs, which cost around 500 € per plate of 90 samples. And the Jurkat-flow test is
511 also completely modular, i.e. each test only comprises the number of samples required,
512 contrary to plate-based assays for which it is rather difficult not to use up a whole plate every
513 time.

514

515 Several reports have already highlighted that using flow-cytometry for the detection of
516 antibodies binding to the S protein expressed at the surface of cells tends to perform better
517 than plate-based assays which use immobilized recombinant proteins (Egia-Mendikute et al.
518 2021; Hambach et al. 2021; Lapuente et al. 2021; Goh et al. 2021; Horndler et al. 2021; Piñero et
519 al. 2021; Grzelak et al. 2020; Ng et al. 2020). This is most likely related to the fact that many
520 antibodies will be binding to conformational epitopes, which will only be found on the naturally
521 expressed and properly folded spike protein. In this regard, the capacity of the S protein to
522 undergo structural fluctuations, particularly at the level of the RBD domain which can be in
523 either an open/up or closed/down conformation, has been shown to influence the binding-
524 capacity of various antibodies (W. T. Harvey et al. 2021; Barnes et al. 2020; Robbiani et al. 2020;
525 Piccoli et al. 2020; Zhou et al. 2020; Huang et al. 2021; Dejnirattisai et al. 2021). This is
526 supported by the results shown in Figure S2, i.e. that, for most samples, we found that
527 incubation at room temperature resulted in a sizeable increase in the amounts of antibodies
528 binding to the spike-expressing cells, suggesting that, at the surface of live cells, the capacity of
529 the spike protein to fluctuate between various conformations will expose different epitopes,
530 and allow the binding of more antibodies.

531

532 One striking aspect of the results shown on Figure 2 is in the difference of performance of
533 the tests between the two cohorts of samples tested. On the one hand, nearly perfect scores
534 were obtained for all three tests on a cohort of sera comprised either of control samples
535 collected before 2019, or of positive sera from PCR-positive Covid-19 patients. On the other
536 hand, the situation was much less clear-cut for the cohort comprising blood samples picked
537 more or less randomly and blindly among those available as left-overs from the hematology
538 department and was, therefore, more akin to a 'real' population. For this second cohort, an
539 additional confounding factor may have been that, since all the samples were from hospitalized
540 patients, some sera may have been poly-reactive due to inflammatory pathologies unrelated to
541 Covid-19.

542

543 All in all, this difference between the two cohorts is reminiscent of the common observation
544 that the performances of clinical tests are often much lower on real populations than those
545 obtained by the manufacturers on very carefully controlled and standardized populations. Our
546 results indeed bring support to the view that the performance of any given serological test will
547 be entirely dependent on the set of samples used to measure it: whilst it is relatively easy to
548 reach an almost perfect score on a cohort comprised only of highly positive and completely
549 negative samples such as the one used for Figure 2A, the situation becomes much less clear
550 when using a set of samples more closely resembling the general population, in which the
551 positive or negative nature of many samples will remain uncertain, and from which it would
552 thus seem futile to try to make precise calculations of sensitivity and specificity. This being said,
553 performing several tests in parallel on such cohorts is very useful to compare the performance
554 of those tests with one another.

556 Several recent reports have underlined the correlation between the serological levels of
557 neutralizing antibodies, which are mostly directed against the RBD, and the degree of protection
558 against becoming infected, or re-infected, by the SARS-Cov-2 virus (Feng et al. 2021; Houry et
559 al. 2021; Garcia-Beltran et al. 2021). Low levels of antibodies are often found in convalescent
560 subjects following asymptomatic infections, and Kalamadasa and colleagues have shown that,
561 whilst HAT sensitivity in such individuals can be as low as 50 %, HAT results are strongly
562 correlated with the seroneutralisation activity in those samples (Kamaladasa et al. 2021). Over
563 the coming months and years, antibodies levels will progressively decrease in both vaccinated
564 and convalescent people, and one of the crucial questions will be that of when to start planning
565 to administer vaccine boosts. Levels of neutralizing antibodies will certainly evolve very
566 differently in different individuals, and an additional difficult aspect will be to define rules for
567 the administration of vaccine boosts, and whether those should be defined as a general rule
568 (e.g. so many months after the initial vaccination), or individually, based on the monitoring the
569 levels of neutralizing antibodies. For such an individually-based approach, HAT would seem to
570 be a particularly appropriate solution since it is a very simple and cheap test based on the
571 binding of antibodies to the RBD domain (Townsend et al. 2021), which are those with
572 neutralizing activity. Furthermore, because the only reagent in HAT simply comprises small
573 amounts of soluble IH4-RBD protein, the hemagglutination test can be very easily adapted to
574 detect antibodies binding to variant forms of the virus (Jayathilaka et al. 2021).

576 Whilst HAT is not as sensitive as an anti-RBD ELISA or the Jurkat-S&R-flow test, this relatively
577 low sensitivity may not really be a problem for using HAT to help decide when to revaccinate
578 people since low levels of antibodies are unlikely to be fully protective. By performing titrations,
579 the HAT assay can also provide a quantitative assessment of the levels of circulating antibodies,
580 which have been shown to correlate strongly with sero-neutralisation titers (Lamikanra et al.
581 2021). In the current version of HAT, however, such a quantification can only be performed in a
582 laboratory environment because it requires separation of the plasma or serum from the red
583 blood cells. Making use of the Jurkat-S&R-flow test as a reference, we are currently in the
584 process of completing work on a modified version of HAT that will be compatible with being
585 performed pretty much anywhere, with no specialized equipment, and will provide a
586 quantitative evaluation of the levels of antibodies in a single step (Joly et al. man in prep.).

587 **Detailed Contributions**

588

589 **Authors**

Name	First name	ORCID	contributions
Maurel Ribes	Agnes	0000-0002-7560-9502	Collected and anonymized blood samples; scored HAT tests, corrected the manuscript
Bessière	Pierre	0000-0001-5657-0027	Provided hamster, cat and dog sera; performed SN; helped perform FACS assays, corrected the manuscript
Guéry	Jean Charles	0000-0003-4499-3270	Provided immunized mouse sera; corrected the manuscript
Joly Featherstone	Eloise	0000-0001-9077-359X	Scored HAT tests
Bruel	Timothée	0000-0002-3952-4261	Provided Jurkat-R and -S cells; corrected the manuscript
Robinot	Rémy	0000-0002-3651-0171	Transduced, selected and grew Jurkat cells
Schwartz	Olivier	0000-0002-0729-1475	Provided Jurkat-R and -S cells
Volmer	Romain	0000-0003-1591-3251	Provided hamster sera
Abravanel	Florence	0000-0002-1753-1065	Provided cohort of sera and ELISA kits
Izopet	Jacques	0000-0002-8462-3234	Provided cohort of sera and ELISA kits; made suggestions for the manuscript
Joly	Etienne	0000-0002-7264-2681	Designed and funded the study; Performed the experiments; Wrote the paper.

590

591 **Other contributors**

Townsend	Alain	Designed the IH4-RBD reagent and funded its production
Tiong	Tan	Produced the IH4-RBD reagent
Rijal	Pramilla	Produced the IH4-RBD reagent
Buchrieser	Julian	Generated lentiviral vectors
Porrot	Françoise	Grew Jurkat cells
Featherstone	Carol	Copy edited parts of the manuscript

592

593 **Acknowledgements**

594

595 The authors are extremely grateful to Alain Townsend, Tiong Kit Tan, Pramila Rijal, Julian
596 Buchrieser and Françoise Porrot, who contributed the various materials detailed in the above
597 table, and to Carol Featherstone for copy editing the manuscript. They also gratefully
598 acknowledge the contributions of Marianne Navarra, for her help in setting up the agreement
599 with the hospital; Miriam Pinilla, Karin Santoni and Etienne Meunier for the gift of Topro-3 and
600 for performing the Mycoplasma tests; Emmanuelle Naser and Pénélope Viana from the IPBS
601 flow cytometry facility for their assistance, and the very helpful staff of the Toulouse EFS.

602 Funding: The first part of this project was funded by a private donation. The second part was
603 funded by the ANR grant HAT-field to EJ.

604 **Materials and Methods**

605

606 **Reagents**

607

608 Polyclonal anti-human and anti-mouse Igs secondary antibodies, all conjugated to Alexa-488,
609 were from Jackson laboratories, and purchased from Ozyme (France) . Refs: anti-human Ig-
610 GAM: 109-545-064, -G: 109-545-003, -A: 109-54-011, -M: 109-545-129; anti-mouse Ig-G: 115-
611 545-003

612

613 Anti-cat IgG (F4262) and anti-dog IgG (F7884) secondary antibodies, both conjugated to FITC,
614 were obtained from Sigma.

615

616 Anti-hamster IgG conjugated to Alexa 647 was obtained from Invitrogen (A-21451)

617

618 Anti RBD monoclonal antibodies: FI3A (site 1) and FD-11A (site 3) (Huang et al. 2021); C121
619 (site 2) (Robbiani et al. 2020); CR3022 (site 4) (ter Meulen et al. 2006); EY6A (site 4) (Zhou et al.
620 2020). All those were obtained using antibody-expression plasmids, as previously described
621 (Townsend et al. 2021).

622

623 The 20/130 WHO reference serum was obtained from the NIBSC (Potters Bar, UK)

624

625 BSA Fraction V was obtained from Sigma (ref A8022).

626

627 PBS and tissue culture media were obtained from Gibco.

628

629 **Generation of Jurkat-S, Jurkat-R and Jurkat-G cell lines**

630 All three cell lines were obtained by means of lentiviral transduction.

631 pLV-EF1a-SARS-CoV-2-S-IRES-Puro was created by cloning a codon-optimized version of the
632 SARS-CoV-2 S gene (GenBank: QHD43416.1) into the pLV-EF1a-IRES-Puro backbone (Addgene
633 plasmid # 85132 ; <http://n2t.net/addgene:85132> ; RRID:Addgene_85132) using BamHI and
634 EcoRI sites.

635

636 The lentiviral vector for the expression of mCherry was obtained by replacing the GFP
637 sequence of GFP by that of mCherry in the pCDH-EF1α-MCS*-T2A-GFP plasmid
638 (<https://systembio.com/shop/pcdh-ef1α-mcs-t2a-gfp-cdna-single-promoter-cloning-and-expression-lentivector/>)

639

640 Lentiviral infectious supernatants were obtained after transient transfection of HEK cells with
641 pLV- or pCDH-derived vectors, together with the packaging R8-2, and VSV-G plasmids.
642 Supernatant was harvested 24h and 48h post transfection, passed through a 45 μm filter and
643 stored in aliquots at -80°C. For the transduction of Jurkat cells, those were distributed in a 6 well
644 plate at 1.5 · 10⁶ cell per well, in a volume of 500 μL of tissue culture medium (RPMI, 10 % FCS,
645 1% PS, 2% Hepes), and 20 μL of the infectious supernatants were added, as well as 5 μL of
646 Lentiblast premium (OZBiosciences). The plate was then spun at 1000g for 60 min at 32°C,
647 before adding 2.5 ml of tissue culture medium and returning the plate to the 37°C incubator.
648 Selection with puromycin was then performed at a concentration of 10μg/mL.

649

649 After a few days, the population of Jurkat cells thus obtained was stained for flow cytometry
analysis using a highly reactive serum from a covid-19 patient, and it was found that most cells

650 expressed the S protein, but at low to intermediate levels. To obtain a population that would
651 express higher levels, we submitted this population to three successive rounds of sterile cell
652 sorting using a FACS Aria Fusion cell sorter (Beckton Dickinson), selecting each time the 5 % of
653 cells with the brightest staining. Cells were placed back in culture and reamplified after each
654 round of selection. At the time of the second round of sorting, the cell sorter was also used for
655 single cell cloning, but all of the dozen clones obtained by this means showed lower expression
656 than the sorted population. The expression of the S protein in the population of Jurkat cells
657 obtained after these three rounds of sorting was found to remain expressed in all cells, and at
658 similar levels, for more than 50 successive passages, over many weeks of continuous cell
659 culture.

660
661 The Jurkat-R cells were obtained by successive transduction with the pCDH-GFP lentiviral
662 vector described above, then with the empty pLV lentiviral vector, followed by selection with
663 Puromycin at 10 µg/mL. FACS analysis revealed that the mCherry fluorescent protein was
664 expressed in 100 % of the cells of the population thus obtained, which therefore did not need to
665 undergo any cell sorting.

666
667 After the initial selection process, both the Jurkat-S and Jurkat-R cell line were maintained in
668 RPMI, 10 % FCS, 2 mM Glutamine, 1% PS and Puromycin at 2.5 µg/mL. The Jurkat-S and Jurkat-R
669 cell lines were both checked for the absence of mycoplasma contamination using the HEK blue
670 hTLR2 kit (Invivogen, Toulouse, France).

671
672 The Jurkat-G cell line was obtained by transduction with the Trip-GFP lentiviral vector
673 (Zennou et al. 2000). Cell sorting was used to bring the 90% of the Jurkat cells that were
674 expressing GFP after the initial transduction to 100 %. The cells were then kept in culture for
675 several dozen passages in standard tissue culture medium with no detectable loss of GFP
676 expression.

677 678 **FACS staining**

679 Before experiments, cells in the cultures of both Jurkat-S and Jurkat-R cell lines were
680 counted, and sufficient numbers harvested to have a bit more than 10^5 cells of each per sample
681 to be tested. Cells from both cell lines were then spun, and resuspended in their own tissue
682 culture medium at a concentration of 2.2×10^6 cells/ mL before pooling equal volumes of the two.

683 Plasmas or sera to be tested were diluted 1/10, either in PBS or in PFN (PBS / 2% FCS / 200
684 mg/L sodium azide). 10 µL of these 1/10 dilutions were then placed in U-bottom 96 well plates,
685 before adding 90 µL per well of the Jurkat-S&R mix.

686 The plates were then incubated for 30 minutes at room temperature before placing them on
687 ice for a further 30 minutes. As can be seen on the supplementary Figure 2, we have found that
688 this initial incubation at room temperature results in a marked increase of the staining signals
689 for most antibodies.

690 All subsequent steps were carried out in the cold, with plates and washing buffers kept on
691 ice. After the primary staining, samples were then washed in PFN, with resuspending the cells
692 by tapping the plate after each centrifugation, and before adding the next wash. After 3 washes,
693 one drop (i.e. ca. 30 µL) of secondary fluorescent antibody diluted 1/200 in PFN was added to
694 each well, and the cells resuspended by gentle shaking of the plates.

695 After an incubation of 60 min on ice, samples were washed two more times with cold PFN
696 before transferring the samples to acquisition tubes in a final volume of 300 ul PFN containing
697 30 nM TO-PRO™-3 Iodide (Thermo Fischer Scientific, ref T3605).

698 This protocol was used for staining with just one pan-specific secondary antibody, i.e. for
699 most of the samples of this study. For specific isotyping, i.e. for staining separately with either
700 anti-IgG, -IgA or -IgM, as well as the pan-specific anti-Ig-GAM secondary antibody, we used
701 double the quantities of cells and of serum or plasma for the primary step, and split the samples
702 into 4 wells after the second wash, before proceeding to the subsequent steps as for the
703 standard protocol.

704 The vast majority of the experiments for this study were analyzed on a FACScalibur flow
705 cytometer controlled by the Cellquest pro software (Version 5.2, Beckton Dickinson), using the
706 FL1 channel for Alexa-488 or FITC, the FL3 channel for m-Cherry, and the FL4 channel (with the
707 633 nm laser) for live gating with the TO-PRO™-3 live stain.

708 For the samples shown on supplementary Figure 1, double quantities were used (as for
709 isotyping) so that the same samples could also be acquired on a Fortessa flow cytometer,
710 controlled by the Diva software (Beckton Dickinson). After the samples had been run on both
711 machines, an equivalent volume of PBS with 2% formaldehyde what added to what was left in
712 the tubes, and those were stored at 4°C for 4 days before they were once again analyzed on
713 both machines.

714 Post-acquisition analysis of all the samples was performed using the Flowjo software (version
715 10.7.1)

716 For the Jurkat-S&G-flow test, Jurkat-R cells were replaced by Jurkat-G cells, we used a
717 secondary antibody conjugated to alexa 647, and TO-PRO™-3 Iodide was replaced by propidium
718 iodide at 2 ug/ml final concentration. The samples were then analyzed on the same FACScalibur
719 flow cytometer, using the FL1 channel for the GFP fluorescence, FL2 for live gating with
720 propidium iodide, and FL4 for the Alexa-647 signals.

721

722 **Cost of the Jurkat-S&R-flow test**

723 The cost per sample of the Jurkat-S&R-flow test lies in large part with the price of the
724 secondary antibodies used. Typically, one vial of secondary antibody costs about 150 € for 1ml,
725 and using 30-50 ul at a 1/200 dilution will provide for at least 5000 samples. The cost of a
726 polyclonal antibody is thus of the order or 3-5 cts per sample.

727 Each sample requires $2 \cdot 10^5$ jurkat cells, which is roughly the amount obtained with 0.5 ml of
728 standard tissue culture medium, which costs around 50 €/L, i.e. 2.5 cts/sample. All in all, if one
729 adds the cost of TC, buffers for the washes and disposable plastics, we estimate that the cost
730 per sample will be of the order of 10 cts.

731 The cost of access to a flow cytometer will be extremely variable between laboratories and
732 institutes. If the cost of access is 20 € per hour, and one runs 200 samples per hour, this will add
733 another 10 cts to the cost per sample.

734

735 **HAT tests**

736 HAT tests were performed using the IH4-RBD reagent diluted at 1 ug/ml in PBN rather than in
737 straight PBS as originally described (Townsend et al. 2021), which results in a slight
738 improvement of the HAT performances, and much improved stability of the IH4-RBD stocks (
739 Joly et al., man in prep.). PBN simply consists of PBS complemented with 1% BSA and 200 mg/L
740 sodium azide. The main role of BSA is to prevent the IH4-RBD reagent from adsorbing onto the

741 plastic of tubes and assay plates, and the azide prevents bacterial and fungal contaminations of
742 the stocks. HAT tests were all performed in V-bottom 96 wells plates (Sarstedt, ref 82 1583).

743 For performing HAT on sera, two tubes of suspension of RBC from an O- donor were
744 prepared at approximately 6 μ L of packed RBC per ml of PBN. The first tube was used to fill the
745 negative control wells with 90 μ L per well. The IH4-RBD reagent was added at 1.1 μ g/ml to the
746 second tube of RBC suspension and this was dispensed at 90 μ L per test well. Sera to be tested
747 were diluted 1/10 in PBS, and 10 μ L of the dilutions were added to a control and a test well.

748 For performing HAT on whole blood samples, which were all leftover clinical samples
749 collected in EDTA tubes (purple tops), 10 μ L were diluted with 60 μ L of PBS + 5 mM EDTA, and
750 10 μ L of this 1/7 dilution were added to each of two wells containing either 90 μ L of PBN for the
751 negative controls, or 90 μ L of PBN containing 1.1 μ g/mL of IH4-RBD reagent for the test wells.

752
753 For both sera and whole blood samples, after 60 minutes incubation at room temperature,
754 the V bottom plates were placed on a homemade light box tilted at an angle of approximately
755 10° from the vertical, and pictures taken with a mobile phone after approximately 20 seconds.

756 In an attempt to increase the sensitivity of the method by detecting partial
757 hemagglutinations, the plates were then returned to a horizontal position for a further two
758 hours, and the procedure of tilting the plate and taking pictures was repeated.

759 As a final step, to ensure that the RBCs in all the 267 blood samples of the second cohort
760 were expressing glycoporphin, 30 μ L of the monoclonal antibody CR3022 diluted at 200 ng/ml in
761 PBN were added to all samples and resuspended by pipetting with a multichannel pipet. The
762 plates were tilted one more after another 60 minutes, and intense hemagglutination was seen
763 in all 267 samples.

764 After transferring all the pictures to computer files, the hemagglutination tests were scored
765 by three independent assessors, of which two were blinded.

766 The scoring system was as follows: A score of 1 was given only to those samples which
767 showed complete hemagglutination after one hour. A score of 0.5 was given to samples which
768 showed either partial hemagglutination after one hour, or partial or complete hemagglutination
769 after the second incubation of 2 hours.

770 This revealed that, whilst there was 100% agreement between the three assessors for the
771 scoring of complete hemagglutination, the scoring of partial hemagglutination proved to be
772 much more subjective and variable, and only those samples which had been scored as partials
773 by all three assessors were finally considered as bona fide partial hemagglutinations.

774

775 **ELISA**

776 The ELISA tests were performed using the WANTAI SARS-CoV-2 Ab ELISA (ref WS-1096),
777 according to the manufacturer's instructions. This commercial kit allows detection of all human
778 antibody isotypes recognizing a recombinant RBD domain of the SARS-Cov-2 virus.

779 The ELISA tests for the cohort of 121 sera were performed in the virology department of the
780 Toulouse hospital, as described previously (Abravanel et al. 2020).

781 The series of ELISA tests for the cohort of 267 plasmas were performed at the IPBS, with the
782 washes being performed by hand rather than by an automated machine, and the 450/625 ODs
783 read by a μ Quant plate reader. All the positive samples of this cohort, as well as a set of
784 randomly selected negatives, were submitted to a repeat of the assay, which showed excellent
785 reproducibility.

786

787 **Human samples**

788 Purpan cohort: The collection of 2019 (negative) and SARS-CoV-2 infected (positive) patients
789 was obtained from the laboratory of virology of the Purpan hospital, as previously described
790 (Abravanel et al. 2020).

791 Rangueil Cohort: The samples were routine care residues from random patients, anonymized
792 within 48 hours of collection, regardless of gender or hospitalization reason, collected in the
793 course of a month between the end of January and the end of February 2021. The Covid status
794 (PCR or positive serology) was unknown to the person performing the Jurkat-S&R-flow, ELISA
795 and HAT experiments. Those whole blood samples were kept at room temperature until being
796 used for HAT assays within 24 hours of obtaining them from the hospital. In trial experiments,
797 we had found that such samples could be stored for up to 5 days without any noticeable
798 difference in the performance of the HAT test.

799 After the whole blood samples had been used for HAT assays, the tubes were then spun, and
800 the plasmas harvested into fresh tubes (to which sodium azide was added at a final
801 concentration of 200 µg/ml). Those harvested plasmas were kept at 4°C until they were used to
802 perform the Jurkat-S&R-flow tests and ELISA tests.

803 Capillary blood: one of the authors of this study collected 50 µL of his own blood by finger
804 pricking, using disposable lancets (Sarstedt ref 85.1016) on various days during the course of
805 his vaccination regimen with the Pfizer/BioNTech vaccine. At the time of collection, the blood
806 samples were diluted with 200 µL of PBS + 5mM EDTA (Since whole blood is roughly 50% RBCs
807 and 50% plasma, this 1/5 dilution of the blood actually corresponds to a 1/10 dilution of the
808 plasma). The plasma was then separated from the RBCs after centrifugation, placed in another
809 tube with sodium azide, and stored at 4°C until the day of the assay.

β10

811 **Experiments on mouse sera**

812 Virus preparation and inactivation

813 SARS-CoV2 was grown on Vero E6 cells (ATCC) in DMEM (Dutscher) supplemented with
814 100 U/mL penicillin, 100 µg/ml streptomycin (Invitrogen), and 2% heat inactivated fetal bovine
815 serum (Sigma). Viral stocks were propagated in 300 cm² flasks (Dutscher) in which 10³ tissue
816 culture infectious dose 50 (TCID₅₀) were inoculated in 100 ml of medium for 3 days at 37°C with
817 5% CO₂. Culture supernatants containing the viral stocks were harvested and inactivated with
818 BPL (Fischer) overnight at 4°C. Virus was then concentrated by ultracentrifugation at 25 000 rpm
819 (for 2 hours at 4°C) on a 20% sucrose cushion in Ultra-Clear centrifuge tubes (SW-32 Ti rotor,
820 Beckman). Pellets were resuspended in PBS, protein concentration was quantified by BCA
821 Protein Assay kit (Pierce). BPL-inactivated SARS-CoV2 stocks at protein concentrations ranging
822 from 1 to 5 µg/µL were stored at -80°C until use.

823 Mouse immunization

824 Mice were injected intra-peritoneally with 15 µg of BPL-SARS-CoV2 in 250 µl of PBS, and then
825 challenged with the same amount at day 62. Mice were euthanized and serum was collected at
826 day 14 post-primary immunization and at day 7 post-secondary challenge. Those experiments
827 were conducted within the scope of the APAFIS licence n° 15236 delivered to Jean Charles
828 Guéry.

β29

830
831 **Experiments on Cat and Dog sera**
832 Serum samples were collected from cats and dogs belonging to owners who developed COVID-
833 19-like symptoms and subsequently tested positive for SARS-CoV-2 infection by RT-qPCR. , at least
834 one month after the owners' recoveries. Samples and data collections were conducted according
835 to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee Sciences
836 et Santé Animale n°115 (protocol code COVIFEL approved on 1 September 2020, registered under
837 SSA_2020_010).

838 Sero-neutralisation assay

839 Serum samples and controls were heat-inactivated at 56 °C for 30 min, serially diluted in
840 DMEM starting at 1:10, mixed with an equal volume of SARS-CoV-2 stock (previously amplified
841 and titrated on Vero-E6 cells and diluted in DMEM to contain 2000 TCID₅₀/ml), incubated for 2
842 hours at 37 °C, and 100 µL transferred to tissue-culture 96 well plates plated with 12.000 Vero-
843 E6 cells per well the day before the assay, in DMEM complemented with 10% of heat-
844 inactivated fetal bovine serum and 1% of penicillin-streptomycin at 37 °C with 5% of CO₂
845 (medium was removed before adding the virus-serum dilutions). After 60 minutes at 37°C, the
846 virus-serum dilutions were removed before adding DMEM complemented with 2% of heat-
847 inactivated fetal bovine serum and 1% of penicillin-streptomycin. Cells were then incubated for
848 72 h at 37 °C with 5% of CO₂. Individual wells were then screened by eye under the microscope
849 for cytopathic effects. Monoclonal anti-SARS-CoV CR3022 antibody (BEI Resources, NIAID, NIH)
850 was used as a positive control. PBS was used as a negative control. Experiments were carried
851 out in a biosafety level 3 facility at the National Veterinary School of Toulouse.

852
853 **Experiments on virally-infected hamsters**
854 Eight week-old female Syrian golden hamsters (*Mesocricetus auratus*, strain RjHan:AURA)
855 from Janvier's breeding Center (Le Genest, St Isle, France) were housed in an animal-biosafety
856 level 3 (A-BSL3), with *ad libidum* access to water and food. Animals were anesthetized with
857 isoflurane and inoculated intranasally with 10⁴ TCID₅₀ units of UCN1 SARS-CoV-2 strain split in
858 20µL in each nostril. SARS-CoV-2 strain UCN1 was amplified as described previously and used at
859 passage 2 (Monchatre-Leroy et al. 2021; Bessière, Wasniewski, et al. 2021). Non-infected
860 animals received the equivalent amount of PBS. Animals were weighted and clinically monitored
861 daily. Six animals from each group were anesthetized and euthanized by exsanguination at 15
862 dpi. Sera were harvested and aliquots were kept frozen until they were needed for the
863 experiments described here.

864 The animal experimentation protocols complied with the regulation 2010/63/CE of the
865 European Parliament and of the council of 22 September 2010 on the protection of animals
866 used for scientific purposes. These experiments were approved by the Anses/ENVA/UPEC ethic
867 committee and the French Ministry of Research (Apafis n°24818-2020032710416319).

868

869 **Ethical statement**

870 All sera from the first cohort, and whole blood samples from the second cohort, were
871 obtained from the Toulouse hospital, where all patients give, by default, their consent for any
872 biological material left over to be used for research purposes after all the clinical tests
873 requested by doctors have been duly completed. Material transfer was done under a signed
874 agreement (CNRS n° 227232, CHU n° 20 427 C). This study was declared and approved by the
875 governing body of the Toulouse University Hospital with the agreement number RnIPH 2021-99,
876 confirming that ethical requirements were fully respected.

877
878 Using such materials, we did not really have control over how representative our cohorts
879 may be, but this allowed us to circumvent the very stringent rules set by French laws regarding
880 the use of human materials for research (RIPH, Loi Jardé). Under those rules, setting up a clinical
881 trial involving biological materials of human origin would require many months of
882 administrative procedures and paperwork, as well as several hundreds of thousands of euros,
883 which we did not have access to.

884
885 For the same reason, the blood samples for the experiment shown on Figure 3A were
886 collected by one of the authors by simple finger-pricking. He did so on his own free will, without
887 the intervention of anybody else, thus circumventing the need for ethical approval.

888
889

890 **Bibliography**

- 891 Abravanel, F., Miédouge, M., Chapuy-Regaud, S., Mansuy, J.-M. and Izopet, J. 2020. Clinical
892 performance of a rapid test compared to a microplate test to detect total anti SARS-CoV-2
893 antibodies directed to the spike protein. *Journal of Clinical Virology* 130, p. 104528.
- 894 Abu-Raddad, L.J., Chemaitelly, H., Coyle, P., et al. 2021. SARS-CoV-2 reinfection in a cohort of
895 43,000 antibody-positive individuals followed for up to 35 weeks. *medRxiv*.
- 896 Adams, E.R., Ainsworth, M., Anand, R., et al. 2020. Antibody testing for COVID-19: A report
897 from the National COVID Scientific Advisory Panel. *Wellcome Open Research* 5, p. 139.
- 898 Amanat, F., Stadlbauer, D., Strohmeier, S., et al. 2020. A serological assay to detect SARS-CoV-
899 2 seroconversion in humans. *Nature Medicine* 26(7), pp. 1033–1036.
- 900 Barnes, C.O., Jette, C.A., Abernathy, M.E., et al. 2020. SARS-CoV-2 neutralizing antibody
901 structures inform therapeutic strategies. *Nature* 588(7839), pp. 682–687.
- 902 Bessièrè, P., Fusade-Boyer, M., Walch, M., et al. 2021. Household Cases Suggest That Cats
903 Belonging to Owners with COVID-19 Have a Limited Role in Virus Transmission. *Viruses*
904 13(4).
- 905 Bessièrè, P., Wasniewski, M., Picard-Meyer, E., et al. 2021. Intranasal type I interferon treatment
906 is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster
907 model. *BioRxiv*.
- 908 Chen, H. 2020. Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-
909 coronavirus-2. *BioRxiv*.
- 910 Chen, Xinhua, Chen, Z., Azman, A.S., et al. 2021. Serological evidence of human infection with
911 SARS-CoV-2: a systematic review and meta-analysis. *The Lancet. Global health* 9(5), pp. e598–
912 e609.
- 913 Dejnirattisai, W., Zhou, D., Ginn, H.M., et al. 2021. The antigenic anatomy of SARS-CoV-2
914 receptor binding domain. *Cell* 184(8), p. 2183–2200.e22.
- 915 Dortet, L., Ronat, J.-B., Vauloup-Fellous, C., et al. 2021. Evaluating 10 Commercially Available
916 SARS-CoV-2 Rapid Serological Tests by Use of the STARD (Standards for Reporting of

917 Diagnostic Accuracy Studies) Method. *Journal of Clinical Microbiology* 59(2).
918 Drózdź, M., Krzyżek, P., Dudek, B., Makuch, S., Janczura, A. and Paluch, E. 2021. Current State
919 of Knowledge about Role of Pets in Zoonotic Transmission of SARS-CoV-2. *Viruses* 13(6).
920 Egia-Mendikute, L., Bosch, A., Prieto-Fernández, E., et al. 2021. Sensitive detection of SARS-
921 CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive
922 antibodies in unexposed individuals. *Communications Biology* 4(1), p. 486.
923 Ertesvåg, N.U., Xiao, J., Zhou, F., et al. 2021. A Rapid Antibody Screening Haemagglutination
924 Test for Predicting Immunity to Sars CoV-2 Variants of Concern. *Research square*.
925 Fani, M., Teimoori, A. and Ghafari, S. 2020. Comparison of the COVID-2019 (SARS-CoV-2)
926 pathogenesis with SARS-CoV and MERS-CoV infections. *Future virology*.
927 Farnsworth, C.W. and Anderson, N.W. 2020. SARS-CoV-2 Serology: Much Hype, Little Data.
928 *Clinical Chemistry* 66(7), pp. 875–877.
929 Feng, S., Phillips, D.J., White, T., et al. 2021. Correlates of protection against symptomatic and
930 asymptomatic SARS-CoV-2 infection. *medRxiv*.
931 Garcia-Beltran, W.F., Lam, E.C., Astudillo, M.G., et al. 2021. COVID-19-neutralizing antibodies
932 predict disease severity and survival. *Cell* 184(2), p. 476–488.e11.
933 Goh, Y.S., Ng, L.F.P. and Renia, L. 2021. A flow cytometry-based assay for serological
934 detection of anti-spike antibodies in COVID-19 patients. *STAR Protocols* 2(3), p. 100671.
935 Grzelak, L., Temmam, S., Planchais, C., et al. 2020. A comparison of four serological assays for
936 detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations.
937 *Science Translational Medicine* 12(559).
938 Hambach, J., Stähler, T., Eden, T., et al. 2021. A simple, sensitive, and low-cost FACS assay for
939 detecting antibodies against the native SARS-CoV-2 spike protein. *Immunity, inflammation and*
940 *disease* 9(3), pp. 905–917.
941 Harvey, R.A., Rassen, J.A., Kabelac, C.A., et al. 2021. Association of SARS-CoV-2 Seropositive
942 Antibody Test With Risk of Future Infection. *JAMA internal medicine* 181(5), pp. 672–679.
943 Harvey, W.T., Carabelli, A.M., Jackson, B., et al. 2021. SARS-CoV-2 variants, spike mutations
944 and immune escape. *Nature Reviews. Microbiology* 19(7), pp. 409–424.
945 Hickey, M.J., Valenzuela, N.M. and Reed, E.F. 2016. Alloantibody generation and effector
946 function following sensitization to human leukocyte antigen. *Frontiers in immunology* 7, p. 30.
947 Horndler, L., Delgado, P., Abia, D., et al. 2021. Flow cytometry multiplexed method for the
948 detection of neutralizing human antibodies to the native SARS-CoV-2 spike protein. *EMBO*
949 *Molecular Medicine* 13(3), p. e13549.
950 Huang, K.-Y.A., Tan, T.K., Chen, T.-H., et al. 2021. Breadth and function of antibody response
951 to acute SARS-CoV-2 infection in humans. *PLoS Pathogens* 17(2), p. e1009352.
952 Jayathilaka, D., Jeewandara, C., Gomes, L., et al. 2021. Comparison of kinetics of immune
953 responses to SARS-CoV-2 proteins in individuals with varying severity of infection and
954 following a single dose of the AZD1222. *medRxiv*.
955 Jeewandara, C., Kamaladasa, A., Pushpakumara, P.D., et al. 2021. Immune responses to a single
956 dose of the AZD1222/Covishield vaccine in health care workers. *Nature Communications* 12(1),
957 p. 4617.
958 Jeffery-Smith, A., Iyanger, N., Williams, S.V., et al. 2021. Antibodies to SARS-CoV-2 protect
959 against re-infection during outbreaks in care homes, September and October 2020. *Euro*
960 *Surveillance* 26(5).
961 Kamaladasa, A., Gunasekara, B., Jeewandara, C., et al. 2021. Comparison of two assays to detect
962 IgG antibodies to the receptor binding domain of SARS-CoV-2 as a surrogate marker for
963 assessing neutralizing antibodies in COVID-19 patients. *International Journal of Infectious*
964 *Diseases* 109, pp. 85–89.
965 Karahan, G.E., Claas, F.H.J. and Heidt, S. 2020. Pre-existing Alloreactive T and B Cells and

966 Their Possible Relevance for Pre-transplant Risk Estimation in Kidney Transplant Recipients.
967 *Frontiers in medicine* 7, p. 340.

968 Khan, S., Nakajima, R., Jain, A., et al. 2020. Analysis of Serologic Cross-Reactivity Between
969 Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray.
970 *BioRxiv*.

971 Khoury, D.S., Cromer, D., Reynaldi, A., et al. 2021. Neutralizing antibody levels are highly
972 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature Medicine*
973 27(7), pp. 1205–1211.

974 Koopmans, M. and Haagmans, B. 2020. Assessing the extent of SARS-CoV-2 circulation
975 through serological studies. *Nature Medicine* 26(8), pp. 1171–1172.

976 Lamikanra, A., Nguyen, D., Simmonds, P., et al. 2021. Comparability of six different
977 immunoassays measuring SARS-CoV-2 antibodies with neutralising antibody levels in
978 convalescent plasma: from utility to prediction. *Transfusion*.

979 Lapuente, D., Maier, C., Irrgang, P., et al. 2021. Rapid response flow cytometric assay for the
980 detection of antibody responses to SARS-CoV-2. *European Journal of Clinical Microbiology &*
981 *Infectious Diseases* 40(4), pp. 751–759.

982 Letizia, A.G., Ge, Y., Vangeti, S., et al. 2021. SARS-CoV-2 Seropositivity and Subsequent
983 Infection Risk in Healthy Young Adults: A Prospective Cohort Study. *SSRN Electronic Journal*.

984 Long, Q.-X., Tang, X.-J., Shi, Q.-L., et al. 2020. Clinical and immunological assessment of
985 asymptomatic SARS-CoV-2 infections. *Nature Medicine* 26(8), pp. 1200–1204.

986 Lumley, S.F., O'Donnell, D., Stoesser, N.E., et al. 2021. Antibody Status and Incidence of
987 SARS-CoV-2 Infection in Health Care Workers. *The New England Journal of Medicine* 384(6),
988 pp. 533–540.

989 ter Meulen, J., van den Brink, E.N., Poon, L.L.M., et al. 2006. Human monoclonal antibody
990 combination against SARS coronavirus: synergy and coverage of escape mutants. *PLoS Medicine*
991 3(7), p. e237.

992 Mohit, E., Rostami, Z. and Vahidi, H. 2021. A comparative review of immunoassays for COVID-
993 19 detection. *Expert review of clinical immunology*.

994 Monchatre-Leroy, E., Lesellier, S., Wasniewski, M., et al. 2021. Hamster and ferret experimental
995 infection with intranasal low dose of a single strain of SARS-CoV-2. *The Journal of General*
996 *Virology* 102(3).

997 Moshe, M., Daunt, A., Flower, B., et al. 2021. SARS-CoV-2 lateral flow assays for possible use
998 in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. *BMJ (Clinical*
999 *Research Ed.)* 372, p. n423.

1000 Ng, K.W., Faulkner, N., Cornish, G.H., et al. 2020. Preexisting and de novo humoral immunity to
1001 SARS-CoV-2 in humans. *Science* 370(6522), pp. 1339–1343.

1002 Piccoli, L., Park, Y.-J., Tortorici, M.A., et al. 2020. Mapping Neutralizing and Immunodominant
1003 Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-
1004 Resolution Serology. *Cell* 183(4), p. 1024–1042.e21.

1005 Piñero, P., Marco De La Calle, F.M., Horndler, L., et al. 2021. Flow cytometry detection of
1006 sustained humoral immune response (IgG + IgA) against native spike glycoprotein in
1007 asymptomatic/mild SARS-CoV-2 infection. *Scientific Reports* 11(1), p. 10716.

1008 Robbiani, D.F., Gaebler, C., Muecksch, F., et al. 2020. Convergent antibody responses to SARS-
1009 CoV-2 in convalescent individuals. *Nature* 584(7821), pp. 437–442.


1010 Sit, T.H.C., Brackman, C.J., Ip, S.M., et al. 2020. Infection of dogs with SARS-CoV-2. *Nature*
1011 586(7831), pp. 776–778.

1012 Townsend, A., Rijal, P., Xiao, J., et al. 2021. A haemagglutination test for rapid detection of
1013 antibodies to SARS-CoV-2. *Nature Communications* 12(1), p. 1951.


1014 Wu, Z., Harrich, D., Li, Z., Hu, D. and Li, D. 2021. The unique features of SARS-CoV-2

1015 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza
1016 virus. *Reviews in medical virology* 31(2), p. e2171.
1017 Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L. and Charneau, P. 2000. HIV-1
1018 genome nuclear import is mediated by a central DNA flap. *Cell* 101(2), pp. 173–185.
1019 Zhou, D., Duyvesteyn, H.M.E., Chen, C.-P., et al. 2020. Structural basis for the neutralization of
1020 SARS-CoV-2 by an antibody from a convalescent patient. *Nature Structural & Molecular*
1021 *Biology* 27(10), pp. 950–958.
1022

Figure S1



Fixed 1% formaldehyde, 4 days @ 4°C



1027 **Figure S1: Using a flow cytometer with a 561 nm Yellow-Green laser improves the mCherry**
1028 **signals**



1029 The same samples shown on Figure 1 were also analyzed on a Fortessa flow cytometer. The
1030 561 nm yellow-green laser was used for the excitation of the mCherry fluorescent protein,
1031 which led to much brighter signals, and thus to much easier separation of the Jurkat-R (mCherry
1032 pos) and Jurkat-S (mCherry neg) populations than when the samples were acquired on a
1033 FACScalibur.

1034 As in figure 1, the numbers in the upper right corners of the histogram overlays plots
1035 correspond to the GMFI of the two histograms (Red: Jurkat-R; green: Jurkat-S), and the big red
1036 numbers to the left of the plots to the RSS. Of note, although the GMFI values were much higher
1037 on the Fortessa than those recorded on the FACScalibur, the RSS values of the various samples
1038 were all very similar between the two machines.

1039
1040 After the samples had been run on both flow cytometers, those were fixed in 1%
1041 formaldehyde by adding an equal volume of PBS + 2% formaldehyde to the remainder of each
1042 sample. The tubes were then stored à 4°C for 4 days before re-analyzing them on both
1043 cytometers. As can be seen on the right hand side of the figure, the red fluorescence of the
1044 mCherry was still detectable on the Fortessa after this procedure of fixation, despite the
1045 intensity of the signals having dropped by about 7 fold. On the FACScalibur, however, this drop
1046 of the mCherry fluorescent signals precluded the separation of the Jurkat-S from the Jurkat-R
1047 cells. If samples are to be fixed, performing the Jurkat-R&S-flow test will thus require access to a
1048 flow cytometer equipped with a 561 nm Yellow-Green laser. As an alternative, we are currently
1049 exploring the possibility of transforming the Jurkat-S&R-flow test into a Jurkat-S&G-flow test,
1050 where the negative control cells would be expressing GFP, which is excited at 488 nm, and using
1051 secondary antibodies conjugated to red fluorochromes such as Alexa647, excited by a 633 nm
1052 red laser, for the detection of the primary antibodies.

1053
1054 Of note, in the dot plots of the Positive and Strong Positive fixed samples, faint clouds of FL1
1055 negative cells can be seen in the mCherry neg window. Those presumably correspond to Jurkat-
1056 R cells which were dead before the fixation step, and from which the mCherry had thus leaked
1057 out. When analyzing populations of live cells, such cells are gated out with the To-pro 3 live
1058 stain, but this no longer works for population of fixed cells. This small problem could probably
1059 be circumvented using a fixable dead cell staining dye such as the LIVE/DEAD Fixable Far Red
1060 stain (ThermoFischer L34973).

1061
1062



1063
1064

1065
1066

Figure S2: Incubation of the samples at room temperature for the first part of the primary staining step markedly improves the staining signals for most antibodies.

1067
1068
1069
1070

For a large fraction of monoclonal and polyclonal antibodies reacting with the Spike protein expressed at the surface of cells, we have repeatedly observed that a step of incubation at room temperature can result in a marked improvement of the staining signals compared to performing the staining continuously on ice.

1071
1072
1073

For this experiment, we selected a panel of 5 monoclonal antibodies reacting with different sites of the spike RBD domain, a panel of 4 plasmas reacting with various intensities, as well the 20/130 reference serum.

1074
1075
1076
1077
1078
1079
1080
1081
1082

For all the samples, we performed eight steps of 3-fold dilutions, and placed 10 ul of the diluted samples in two parallel U bottom 96 well plates. The first plate was kept at room temperature (RT) whilst the other one was placed on ice. The Jurkat-S&R mix was then added to the wells of the plate at room temperature. The tube was then placed on ice for a few minutes, before distributing the mix in the wells of the second plate. After 30 minutes, the plate which had been sitting at room temperature was also placed on ice, and incubated for another 30 minutes. The rest of the staining procedure was then exactly the same for the two plates, all performed in the cold as described in M&M.

	Sample ID	IgGAM			IgG			IgA			IgM			G+A+M	Fraction IgG signal	Fraction IgA signal	Fraction IgM signal
		GMFI Jurkat R	GMFI Jurkat S	specific stain S - J-R (J _r)	GMFI Jurkat R	GMFI Jurkat S	specific stain S - J-R (J _r)	GMFI Jurkat R	GMFI Jurkat S	specific stain S - J-R (J _r)	GMFI Jurkat R	GMFI Jurkat S	specific stain S - J-R (J _r)				
Sera	neg	1.87	2.01	0.14	1.95	1.99	0.04	1.79	2.13	0.34	1.89	1.98	0.09	0.47			
	30/120	3.19	760	756.81	3.59	763	759.41	2.11	63.2	61.09	2.74	640	637.26	1457.76	0.52	0.04	0.44
	<J14-3	5.1	51.6	46.5	7.47	57.2	49.73	3.08	29.1	26.02	2.55	8.65	6.1	81.85	0.61	0.32	0.07
	<J14-29	4.59	738	733.41	5.16	919	913.84	2.77	122	119.23	2.54	203	200.46	1233.53	0.74	0.10	0.16
	<J14-32	4.71	1692	1687.29	5.25	2350	2344.75	4.01	610	605.99	2.56	402	399.44	3350.18	0.70	0.18	0.12
	<J14-35	4.65	198	193.35	4.82	209	204.18	1.97	52.6	50.63	3.14	13.1	9.96	264.77	0.77	0.19	0.04
	<J14-109	6.52	852	845.48	6.23	1082	1075.77	2.61	179	176.39	4.55	126	121.45	1373.61	0.78	0.13	0.09
	<J14-130	8.7	150	141.3	9.46	151	141.54	3.28	45.7	42.42	5.25	58.1	52.85	236.81	0.60	0.18	0.22
	>J14-40	4.84	54.9	50.06	6.07	54.3	48.23	2.18	12	9.82	2.76	29.1	26.34	84.39	0.57	0.12	0.31
	neg-2213	10.5	33.3	22.8	12.3	43.3	31	3.21	6.58	3.37	6.12	8.77	2.65	37.02	0.84	0.09	0.07
	neg-2649	19.2	41.4	22.2	24.7	56.2	31.5	6.32	9.59	3.27	6.15	9.62	3.47	38.24	0.82	0.09	0.09
	Plasmas	2	438	1427	989	577	1846	1269	59.4	469	409.6	739	1333	594	2272.60	0.56	0.18
18		7.82	84.9	77.08	11.3	101	89.7	2.67	33.4	30.73	4.89	12.7	7.81	128.24	0.70	0.24	0.06
19		2.02	2.2	0.18	2.07	2.15	0.08	1.82	2.18	0.36	1.83	1.96	0.13	0.57			
36		4.53	88.7	84.17	5.01	90.2	85.19	2.38	48.5	46.12	3.61	10.4	6.79	138.10	0.62	0.33	0.05
47		3.47	139	135.53	3.65	141	137.35	2.15	47.1	44.95	2.8	42.2	39.4	221.70	0.62	0.20	0.18
56		9.03	25.7	16.67	9.48	26.8	17.32	2.56	17.2	14.64	7.16	11.2	4.04	36.00	0.48	0.41	0.11
57		5.84	25.5	19.66	7.04	26.7	19.66	2.17	8.87	6.7	4.55	13.9	9.35	35.71	0.55	0.19	0.26
73		3.87	130	126.13	3.61	159	155.39	1.91	4.35	2.44	3.1	4.64	1.54	159.37	0.98	0.02	0.01
80		2.5	82	79.5	3.07	99.1	96.03	2.06	2.75	0.69	2.21	2.56	0.35	97.07	0.99	0.01	0.00
83		3.13	1674	1670.87	3.69	1900	1896.31	2.21	542	539.79	2.4	629	626.6	3062.70	0.62	0.18	0.20
88		3.74	1110	1106.26	4.18	1297	1292.82	2.51	159	156.49	3.03	632	628.97	2078.28	0.62	0.08	0.30
108		3.53	7.65	4.12	4.22	9.66	5.44	2.08	2.61	0.53	2.6	3.58	0.98	6.95			
123		54.5	75.6	21.1	51.6	71.4	19.8	4.22	6.14	1.92	43.5	61.1	17.6	39.32	0.62	0.08	0.30
161		2.91	5.84	2.93	6.17	11.1	4.93	2.08	2.59	0.51	2.09	2.25	0.16	5.60			
166		101	162	61	109	176	67	27.2	35.3	8.1	46.5	68.9	22.4	97.50	0.69	0.08	0.23
174		3.11	190	186.89	4.43	228	223.57	2.45	50.1	47.65	2.19	42.3	40.11	311.33	0.72	0.15	0.13
177		7.9	1945	1937.1	8.04	2303	2294.96	2.32	581	578.68	7.58	699	691.42	3565.06	0.64	0.16	0.19
227		4.12	77	72.88	5.31	51.4	46.09	2.83	6.19	3.36	3	73.8	70.8	120.25	0.38	0.03	0.59
232		11	131	120	12.6	169	156.4	6.21	9.13	2.92	4.84	6.83	1.99	161.31	0.97	0.02	0.01
241		4.11	2411	2406.89	4.61	2860	2855.39	2.6	608	605.4	2.83	47.8	44.97	3505.76	0.81	0.17	0.01
247	13.8	23.3	9.5	21.6	31.7	10.1	8.87	15.7	6.83	3.5	5.88	2.38	19.31	0.52	0.35	0.12	
253	3.98	28.2	24.22	5.22	33	27.78	2.43	10.7	8.27	2.43	2.9	0.47	36.52	0.76	0.23	0.01	
260	23.2	33.9	10.7	30.8	44.1	13.3	29.4	43	13.6	5.98	7.61	1.63	28.53	0.47	0.48	0.06	

1083

1084 **Table S1:** Example of isotyping performed on a representative set of various serum and
1085 plasma samples.

1086 As can be seen on the right hand side portion of the table, comparison of samples from
1087 different patients shows that there can be large variations in the proportions of Ig-G,-A and -M.
1088 Because polyclonal secondary antibodies will not all react with their targeted primary antibodies
1089 with the same efficiency, however, the actuals signals for the various subclasses of antibodies
1090 should not be taken as a true reflection of the amounts of each subclass of antibody.

1091 If a more quantitative evaluation was needed, monoclonal secondary antibodies could be
1092 used instead of polyclonal reagents, making sure that all those isotypes-specific secondary
1093 monoclonal antibodies were being used well above the saturating concentration, and
1094 conjugated to similar amounts of the same fluorochrome. This would, however, increase the
1095 cost of the procedure considerably.

1096